TGF-beta may help prevent postop scarring, studies say

WURZBURG, Germany — Monoclonal antibodies are a promising modality for prevention of scarring after trabeculectomy, according to current research. Several studies are investigating the interaction between growth factors and their role in the induction of postoperative scarring of the filtering bleb, an analysis of published studies concludes.

I. Wimmer and colleagues note in the September issue of Der Ophthalmologe that among the growth factors being studied in several trials, TGF-beta 2 plays a key regulatory function. Its concentration in the aqueous humor of patients with primary open-angle glaucoma is significantly elevated, and both in vivo and in vitro studies have shown the growth factor to demonstrate “promising inhibition of scarring after subconjunctival application.” In addition, current research indicates the growth factor is a safe and well-tolerated approach to managing postop scarring.